Novel agent abelacimab has potential to be a safer anticoagulant, according to the randomized AZALEA-TIMI 71 trial. The trial had been stopped early because of a surprisingly large reduction in bleeds ...

A pair of Regeneron’s monoclonal antibodies have held their own against a commonly used anticoagulant in a phase 2 trial, with one of the candidates also matching Bristol Myers Squibb and Pfizer’s ...

DUBLIN--(BUSINESS WIRE)--The "Anticoagulants Market Global Forecast Report by Drug Class, Route of Administration, Distribution Channel, Application, Countries and Company Analysis 2025-2033" report ...

Mylan on Sept. 8 signed a deal to acquire South African drugmaker Aspen Pharmacare’s thrombosis business in Europe for $757 million. The Canonsburg, Pa.-based drugmaker will gain rights for Aspen’s ...